vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Wingstop Inc. (WING). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $183.7M, roughly 1.5× Wingstop Inc.). Wingstop Inc. runs the higher net margin — 16.3% vs -45.7%, a 61.9% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 7.4%). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 8.6%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Wingstop Inc. is an American international fast food chain that primarily sells buffalo wings. Wingstop locations are decorated with a 1930s and 1940s pre-jet aviation theme.
GH vs WING — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $183.7M |
| Net Profit | $-128.5M | $29.9M |
| Gross Margin | 64.6% | 86.5% |
| Operating Margin | -43.0% | 27.4% |
| Net Margin | -45.7% | 16.3% |
| Revenue YoY | 39.4% | 7.4% |
| Net Profit YoY | -15.8% | — |
| EPS (diluted) | $-1.01 | $1.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $183.7M | ||
| Q4 25 | $281.3M | $175.7M | ||
| Q3 25 | $265.2M | $175.7M | ||
| Q2 25 | $232.1M | $174.3M | ||
| Q1 25 | $203.5M | $171.1M | ||
| Q4 24 | $201.8M | $161.8M | ||
| Q3 24 | $191.5M | $162.5M | ||
| Q2 24 | $177.2M | $155.7M |
| Q1 26 | — | $29.9M | ||
| Q4 25 | $-128.5M | $26.8M | ||
| Q3 25 | $-92.7M | $28.5M | ||
| Q2 25 | $-99.9M | $26.8M | ||
| Q1 25 | $-95.2M | $92.3M | ||
| Q4 24 | $-111.0M | $26.8M | ||
| Q3 24 | $-107.8M | $25.7M | ||
| Q2 24 | $-102.6M | $27.5M |
| Q1 26 | — | 86.5% | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | 85.6% | ||
| Q3 24 | 61.1% | 85.0% | ||
| Q2 24 | 59.1% | 85.4% |
| Q1 26 | — | 27.4% | ||
| Q4 25 | -43.0% | 26.7% | ||
| Q3 25 | -37.3% | 27.9% | ||
| Q2 25 | -45.9% | 25.9% | ||
| Q1 25 | -54.6% | 22.4% | ||
| Q4 24 | -62.4% | 25.9% | ||
| Q3 24 | -61.3% | 24.5% | ||
| Q2 24 | -56.8% | 26.5% |
| Q1 26 | — | 16.3% | ||
| Q4 25 | -45.7% | 15.2% | ||
| Q3 25 | -35.0% | 16.2% | ||
| Q2 25 | -43.0% | 15.4% | ||
| Q1 25 | -46.8% | 53.9% | ||
| Q4 24 | -55.0% | 16.5% | ||
| Q3 24 | -56.3% | 15.8% | ||
| Q2 24 | -57.9% | 17.7% |
| Q1 26 | — | $1.08 | ||
| Q4 25 | $-1.01 | $0.99 | ||
| Q3 25 | $-0.74 | $1.02 | ||
| Q2 25 | $-0.80 | $0.96 | ||
| Q1 25 | $-0.77 | $3.24 | ||
| Q4 24 | $-0.90 | $0.91 | ||
| Q3 24 | $-0.88 | $0.88 | ||
| Q2 24 | $-0.84 | $0.93 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $128.8M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | — |
| Total Assets | $2.0B | $648.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $128.8M | ||
| Q4 25 | $378.2M | $196.6M | ||
| Q3 25 | $580.0M | $237.6M | ||
| Q2 25 | $629.1M | $227.9M | ||
| Q1 25 | $698.6M | $251.4M | ||
| Q4 24 | $525.5M | $315.9M | ||
| Q3 24 | $585.0M | $84.0M | ||
| Q2 24 | $933.7M | $96.7M |
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | $1.2B | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | $1.2B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $-99.3M | $-736.8M | ||
| Q3 25 | $-354.5M | $-702.6M | ||
| Q2 25 | $-305.5M | $-686.0M | ||
| Q1 25 | $-250.8M | $-715.0M | ||
| Q4 24 | $-139.6M | $-675.6M | ||
| Q3 24 | $-60.1M | $-447.5M | ||
| Q2 24 | $-1.6M | $-437.5M |
| Q1 26 | — | $648.9M | ||
| Q4 25 | $2.0B | $693.4M | ||
| Q3 25 | $1.3B | $721.0M | ||
| Q2 25 | $1.3B | $708.3M | ||
| Q1 25 | $1.3B | $696.8M | ||
| Q4 24 | $1.5B | $716.2M | ||
| Q3 24 | $1.5B | $484.8M | ||
| Q2 24 | $1.6B | $451.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | — |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-26.4M | $57.3M | ||
| Q3 25 | $-35.4M | $63.9M | ||
| Q2 25 | $-60.3M | $6.6M | ||
| Q1 25 | $-62.7M | $25.3M | ||
| Q4 24 | $-64.5M | $7.7M | ||
| Q3 24 | $-51.1M | $69.0M | ||
| Q2 24 | $-94.0M | $36.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-54.2M | $34.5M | ||
| Q3 25 | $-45.8M | $61.7M | ||
| Q2 25 | $-65.9M | $-7.8M | ||
| Q1 25 | $-67.1M | $17.3M | ||
| Q4 24 | $-83.4M | $-8.6M | ||
| Q3 24 | $-55.3M | $54.9M | ||
| Q2 24 | $-99.1M | $25.9M |
| Q1 26 | — | — | ||
| Q4 25 | -19.3% | 19.6% | ||
| Q3 25 | -17.3% | 35.1% | ||
| Q2 25 | -28.4% | -4.5% | ||
| Q1 25 | -33.0% | 10.1% | ||
| Q4 24 | -41.3% | -5.3% | ||
| Q3 24 | -28.9% | 33.8% | ||
| Q2 24 | -55.9% | 16.6% |
| Q1 26 | — | — | ||
| Q4 25 | 9.9% | 13.0% | ||
| Q3 25 | 3.9% | 1.3% | ||
| Q2 25 | 2.4% | 8.2% | ||
| Q1 25 | 2.2% | 4.7% | ||
| Q4 24 | 9.4% | 10.1% | ||
| Q3 24 | 2.2% | 8.7% | ||
| Q2 24 | 2.9% | 6.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.14× | ||
| Q3 25 | — | 2.24× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 0.27× | ||
| Q4 24 | — | 0.29× | ||
| Q3 24 | — | 2.68× | ||
| Q2 24 | — | 1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
WING
| Royalty revenue, franchise fees and other | $87.5M | 48% |
| Advertising fees | $63.3M | 34% |
| Company-owned restaurant sales | $33.0M | 18% |
